Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Actuate Therapeutics, Inc.. The associated price target remains the same with $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Actuate Therapeutics, Inc.’s strategic regulatory plans and promising clinical data. The company’s management is actively pursuing Breakthrough Therapy Designation for elraglusib, which could accelerate its approval process through the Real-Time Oncology Review program. This strategic move is bolstered by positive data from a Phase 2 study, showing significant improvement in survival rates for patients treated with elraglusib in combination with other therapies.
Furthermore, the financial projections and valuation analysis support a positive outlook. Despite reporting no revenues for 2Q25, the company’s cash reserves are deemed sufficient to sustain operations into late 2025. The analyst’s valuation, based on a risk-adjusted net present value analysis, suggests a 12-month price target of $20 per share. However, potential risks such as financial, clinical, and regulatory challenges are acknowledged, yet the overall assessment leans towards a favorable long-term potential for ACTU.